Pathos AI Raises $237M, Partners with Bristol Myers Squibb and Tempus AI for Neuroscience Push
8 Sources
[1]
AI drug development startup Pathos AI closes $237M investment
Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation. Pharmaceutical giant Bristol Myers Squibb Co. led the Series E round with participation from several unnamed returning backers. Pathos' investor roster includes big names such as AstraZeneca plc,
[2]
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development
Pathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders. Pathos AI also raised $237 million in a Series E funding round led by Bristol
[3]
Pathos AI Expands Beyond Oncology with BMS and Tempus Neuroscience Partnerships
Pathos AI has partnered with Bristol Myers Squibb and Tempus AI to use agentic AI and clinical data to speed up neuroscience drug development, with an initial focus on Alzheimer's disease. Pathos AI signed two collaborations with Bristol Myers Squibb (BMS) and Tempus AI to accelerate drug
[4]
Tempus AI enters data licensing agreements with BMS and Pathos AI worth $192.5 million By Investing.com
Tempus AI, Inc. (NASDAQ:TEM) announced Friday it has entered into a series of agreements with Bristol-Myers Squibb Company (NYSE:BMY) and Pathos AI, Inc. to expand access to Tempus's de-identified multimodal real-world data, data analysis software, agentic tools, and machine learning models.
[5]
Tempus AI, Inc. Enters Into Multi-Year Agreement With Bristol Myers Squibb To License Multimodal Oncology Data
Tempus AI, Inc. announced a multi-year agreement with Bristol Myers Squibb, under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology
[6]
Pathos AI Announces Strategic Collaborations With Bristol Myers Squibb And Tempus AI, Inc. To Advance AI-Driven Drug Development Beginning With Alzheimer?s Disease And Other Neurological Conditions
Pathos AI announced multi-year strategic collaborations with Bristol Myers Squibb and Tempus AI, Inc. to build a specialized, curated dataset and agentic AI capabilities for Alzheimer?s disease and other neurological conditions. Tempus will apply the infrastructure and expertise it has built in
[7]
Pathos AI partners with Bristol Myers Squibb and Tempus AI to accelerate medical research
Pathos AI announced a partnership with Bristol Myers Squibb and Tempus AI to harness artificial intelligence in the development of treatments for Alzheimer's disease and other neurological disorders. The collaboration comes with a $237m Series E funding round led by Bristol Myers Squibb, valuing
[8]
Tempus AI Expands Bristol Myers Partnership With Multi-Year Oncology, AI Data Deals
Tempus AI signed a multi-year deal with Bristol Myers Squibb to license oncological data and provide access to its artificial intelligence-powered platform. Under the terms of the deal, Bristol Myers will gain access to Tempus's Lens Platform, the company's agentic AI platform for oncology drug
Share
Copy Link
Pathos AI secured $237 million in Series E funding at a $3 billion valuation, led by Bristol Myers Squibb. The company is expanding beyond oncology into neuroscience drug development through strategic partnerships with Bristol Myers Squibb and Tempus AI, focusing on Alzheimer's disease research using its AI-driven Foundry platform.
Pathos AI Secures Major Funding and Strategic Partnerships
Pathos AI closed a $237 million Series E funding round at a $3 billion valuation, with Bristol Myers Squibb leading the investment
1
. The deal marks a significant expansion for the New York-based biotech company, which has attracted backing from pharmaceutical giants including AstraZeneca, NEA, and General Atlantic1
. Bristol Myers Squibb gains non-exclusive strategic access to the Pathos Foundry platform across its broader portfolio, along with three-year exclusive rights to use the platform for its neuroscience development programs2
.
Source: ET
Strategic Pivot into Neuroscience Drug Development
The partnerships represent Pathos AI's first major move beyond oncology, placing Alzheimer's disease at the center of its new neuroscience strategy
3
. The company will combine its agentic AI platform with Tempus AI's large-scale clinical datasets and Bristol Myers Squibb's neuroscience expertise to accelerate drug development for neurological disorders3
. This collaboration aims to support the design of adaptive clinical trials for Alzheimer's disease and related conditions, leveraging AI-driven research to improve understanding of disease progression and treatment outcomes3
.Data Licensing Agreements Worth $192.5 Million
Pathos AI commissioned Tempus AI to build a comprehensive dataset covering hundreds of thousands of patients with neurological conditions under a five-year, $55 million agreement
2
. Tempus will deliver up to 500,000 de-identified records of patients with Alzheimer's disease or other neurological disorders at a rate of 100,000 records per year, with payments consisting of $50 million in data license fees and $5 million for record updates4
. The broader data licensing agreements between Tempus AI, Bristol Myers Squibb, and Pathos AI will provide Tempus with aggregate cash payments of up to $192.5 million over approximately five years4
.Pathos Foundry Platform Powers AI Drug Development
The Pathos Foundry platform has access to approximately 200 petabytes of oncological data and uses AI agents to pinpoint the most promising drug candidates from hundreds of potential molecules
1
. According to Pathos CEO Iker Huerga, "Foundry has fundamentally accelerated our ability to identify highly promising clinical assets and integrate them into our pipeline"1
. The platform analyzes real-world multimodal datasets to help researchers identify patients who could benefit most from each therapy and plan biomarker-driven clinical trials1
.
Source: SiliconANGLE
Related Stories
Oncology Pipeline and Cancer Drug Development
Pathos AI stated that its key priority remains its JSKN016 program, which aims to develop a cancer therapy based on an antibody-drug conjugate
1
. Antibody-drug conjugates are upgraded antibodies containing an antigen with therapeutic properties that attach to cancer cells and cause them to absorb the molecule, which neutralizes them1
. The company will use Series E funding to finance three other drug programs, including a collaboration with AstraZeneca to develop an ER PROTAC drug that harnesses cells' built-in material recycling mechanism to treat cancer1
.
Source: Market Screener
Tempus Expands Oncology Data Access for Bristol Myers Squibb
Bristol Myers Squibb significantly expanded its strategic relationship with Tempus AI through a multi-year agreement running through 2031, under which BMS will license multimodal oncology data to support biological and clinical insight identification, novel drug target discovery, and therapeutic development across its oncology portfolio
5
. BMS will pay fixed payments totaling $137.5 million, invoiced quarterly, and gain access to Tempus Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world's largest real-world multimodal datasets4
5
. With this agreement, BMS becomes one of Tempus's largest licensors of de-identified oncology data5
.References
Summarized by
Navi
[1]
[3]
[4]
Related Stories
Pathos AI Secures $365 Million in Series D Funding to Advance AI-Powered Oncology Drug Development
16 May 2025•Business and Economy
Bristol-Myers Squibb deploys Anthropic's Claude AI across 30,000 employees to speed drug discovery
21 May 2026•Technology
Tempus AI Soars on $200 Million AstraZeneca Deal for AI-Powered Cancer Research
24 Apr 2025•Business and Economy
Recent Highlights
1
AI Discovers Critical PHP Vulnerability Exposing 70% of Websites to Remote Code Execution
Technology
2
OpenAI AI Agents Disabled Safety Monitoring During Internal Tasks, Then Lied About It
Policy and Regulation
3
OpenAI AI Models Hacked Crypto Wallet, Breached Government Sites in Unauthorized Activities
Technology
Recent Highlights
Today's Top Stories
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Follow topics that matter to you and stay ahead.
